| |
Revolutionize your clinical trial! IQVIA experts discuss how the synergy between wearables and eCOA will enhance data collection, patient engagement, regulatory compliance and streamline trial processes. Watch this webinar replay now.
|
|
Today’s Big NewsJul 17, 2025 |
| By Gabrielle Masson Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. |
|
|
|
By James Waldron Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined efficacy thresholds” in a phase 2 study. |
By Nick Paul Taylor BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to "pursue new professional opportunities." |
Sponsored by Evernorth Specialty Services Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, therapy fulfillment and generalized patient care. |
|
Overcome biotherapeutic protein expression challenges with advanced vector technology for a range of multi-gene and difficult to express proteins. Watch the presentation to learn more.
|
|
By Gabrielle Masson Otsuka Pharmaceutical is putting down $33 million cash for a Swedish biotech’s IL1RAP antibodies designed to treat autoimmune and inflammatory diseases. |
By James Waldron I-Mab has solidified its pivot to givastomig by buying out the owner of an antibody used in the therapy. |
By Darren Incorvaia Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition. Okyo Pharma’s urcosimod reduced pain levels by an average of 5.5 on a 10-point scale, hitting the primary endpoint of a phase 2 trial and teeing up a meeting with the FDA about next steps. |
By Zoey Becker The FDA listed observations at plants run by Sun Pharma, Daewoo Pharmaceutical and Glenmark, citing concerns ranging from mold to quality control issues. |
By Angus Liu The FDA is asking an expert panel to weigh in on “discordant results” from three randomized trials related to Lundbeck and Otsuka's application for a Rexulti combination regimen in PTSD. |
By Fraiser Kansteiner Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ubiquitous antibiotic. |
By Conor Hale “We are not rolling over,” J&J MedTech’s worldwide chairman, Tim Schmid, said on the company’s quarterly earnings call with investors. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "Podnosis," we explore how Walmart heir Alice Walton’s new medical school in Arkansas is rethinking medical education with a whole health approach that values empathy, the arts and business alongside clinical training. |
|
|---|
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| |
|
